NasdaqGS:AMGNBiotechs
Amgen Lawsuit And Eczema Drug Exit Reframe Risk And R&D Priorities
Amgen (NasdaqGS:AMGN) is being sued over its decision to withdraw certain discounted drug prices from Sagebrush Health Services, a clinic serving underserved patients in California.
The lawsuit claims Amgen’s actions unlawfully restricted access to lower cost medicines for economically challenged communities and may breach state law.
Separately, Amgen has ended its collaboration with Kyowa Kirin on rocatinlimab, an investigational treatment for atopic dermatitis.
The end of the rocatinlimab...